Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma
Conditions
Keywords
Glucocorticoid Receptor, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Nab-paclitaxel, Glucocorticoid Receptor Antagonist, Relacorilant
Brief summary
This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or continuous regimens of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel alone.
Detailed description
Relacorilant is a small molecule antagonist of the glucocorticoid receptor (GR). The goals of this study are to evaluate the efficacy of relacorilant either administered daily (continuous) or on the day prior, the day of, and the day after chemotherapy (intermittent) in combination with nab-paclitaxel in the treatment of platinum-resistant ovarian, fallopian tube, or primary peritoneal cancers compared with nab-paclitaxel alone. The safety, pharmacokinetics (PK), and pharmacodynamic profile of relacorilant in combination with nab-paclitaxel will also be assessed. Eligible patients will be randomized 1:1:1 to one of the following three treatment arms. Patient randomization will be stratified by treatment-free interval from most recent taxane (relapsed within 6 months vs \>6 months) and presence of ascites (yes vs no). * Arm A (Continuous relacorilant): Relacorilant starting at 100 mg, administered orally, once daily every day in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle. * Arm B (Intermittent relacorilant): Relacorilant 150 mg, administered orally, on the day before (excluding Cycle 1, Day -1), the day of, and the day after nab-paclitaxel, in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle. * Arm C (Comparator): Nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle. Patients will remain on study treatment until reaching a protocol-defined event of disease progression (PD), experiencing unmanageable toxicity, or until other treatment discontinuation criteria are met. All patients will be followed for progression, subsequent therapies, and survival in the long-term follow-up phase. Patients in Arm C who experience unequivocal PD per RECIST v1.1 will be given the opportunity to receive relacorilant in combination with nab-paclitaxel after discussion with the Medical Monitor (Crossover patients).
Interventions
DRUGRelacorilant
Relacorilant is supplied as capsules for oral dosing.
DRUGNab-paclitaxel
Nab-paclitaxel is administered as IV infusion over 30-40 minutes.
Sponsors
Corcept Therapeutics
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed and dated Investigational Review Board/Independent Ethics Committee-approved informed consent form (ICF) prior to study-specific screening procedures. * Female patients aged ≥18 years old at time of consent * Histologic diagnosis of high grade serous or endometrioid epithelial ovarian, primary peritoneal, or fallopian tube cancer or ovarian carcinosarcoma. Clear cell, mucinous and borderline histologic subtypes are excluded. * Received at least 1 line of therapy with evidence of cancer progression within 6 months after the last dose of platinum-based therapy (ie, having a platinum-free interval of ≤6 months \[platinum resistant\]), or progressive disease during or immediately after primary platinum-therapy, (ie, platinum refractory). Patients with primary platinum resistance (progression within 6 months of the last dose of first-line platinum-containing chemotherapy) are considered eligible. Notes: For the calculation of the platinum-free interval, cancer progression must be defined by clear evidence of progression, such as radiographic progression per RECIST v1.1. Calculating the platinum-free interval on the basis of increased Cancer Antigen (CA-125) is not allowed. * Measurable or non-measurable disease by RECIST v1.1: * Previously irradiated lesions are not allowed as measurable disease, unless there is documented evidence of progression in the lesions. * To be eligible with non-measurable disease, patients must have evaluable disease with CA 125 at least twice the upper limit of reference range (of CA-125 ≥70 U/mL), along with radiographically evaluable disease by computerized tomography (CT)/magnetic resonance imaging (MRI). * Availability and consent to provide tumor tissue for biomarker assays (archival or recent biopsy). * No more than 4 prior chemotherapeutic or myelosuppressive regimens (not including maintenance therapy such as single-agent bevacizumab or poly (ADP-ribose) polymerase \[PARP\] inhibitors). Patients with platinum-refractory cancer cannot have had more than 2 prior lines of treatment for refractory disease. * Appropriate to treat with nab-paclitaxel, in the opinion of the Investigator. * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. * Adequate organ and bone marrow function meeting the following criteria at the Screening Visit: * Absolute neutrophil count (ANC) ≥1,500 cells/mm\^3. * Platelet count ≥100,000/mm\^3. * Hemoglobin ≥9 g/dL. * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤2.5 × upper limit of normal (ULN) (or ≤5 × ULN in the context of liver metastasis). * Total bilirubin ≤1.5 × ULN. * Creatinine clearance ≥45 mL/min/1.73 m\^2 (measured or estimated). * Albumin ≥3 g/dL (≥30 g/L) . * If patient has undergone surgery of the gastrointestinal or hepatobiliary tract, adequate absorption as evidenced by: albumin ≥3.0 g/dL, controlled pancreatic insufficiency (if present), and lack of malabsorption. * Able to swallow and retain oral medication and does not have uncontrolled emesis. * Able to comply with protocol requirements. * Negative pregnancy test for patients of childbearing potential. Patients of childbearing potential must use appropriate precautions to avoid pregnancy, defined as of non-childbearing potential (ie, postmenopausal or permanently sterilized) or using highly effective contraception with low user-dependency, for at least 3 months after the last dose of relacorilant, or per the duration indicated in the product label for nab-paclitaxel, whichever is latest. A woman is postmenopausal if it is more than 12 months since her last menstruation, without an alternative medical cause. Accepted methods of permanent sterilization methods are hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy. Accepted methods of highly effective contraception with low-user-dependency are: * An intrauterine device (IUD), provided that the subject has tolerated its use for at least 3 months before the first dose of study medication and undertakes not to have it removed for 1 month after the last dose. * Abstinence from heterosexual intercourse, when it is in line with the subject's preferred and usual lifestyle. Periodic abstinence and withdrawal are NOT acceptable. * Vasectomized partner provided that the partner is the sole sexual partner of the trial participant and that the vasectomized partner has received medical assessment of the surgical success. * Oral hormonal contraceptives are NOT permitted.
Exclusion criteria
* Clinically relevant toxicity from prior systemic anticancer therapies or radiotherapy that in the opinion of the Investigator has not resolved to Grade 1 or less prior to randomization. * Any major surgery within 4 weeks prior to randomization. If subject received major surgery including (curative or palliative surgery), they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy. * Treatment with the following prior to randomization: * Concurrent treatment with other anticancer therapy including other chemotherapy, immunotherapy, radiotherapy, chemoembolization, targeted therapy, an investigational agent or the non-approved use of a drug or device within 28 days before the first dose of study drug. * Hormonal anticancer therapies within 7 days of the first dose of study drug. * Systemic, inhaled, or prescription strength topical corticosteroids within 21 days of the first dose of study drug. Short courses (≤5 days) for non-cancer-related reasons are allowed if clinically required (such as prophylaxis for CT). * Received radiation to more than 25% of marrow-bearing areas. * Toxicities of prior therapies (except alopecia) that have not resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 ≤Grade 1. * Requirement for treatment with chronic or frequently used oral corticosteroids for medical conditions or illnesses (eg, rheumatoid arthritis, immunosuppression after organ transplantation). * History of severe hypersensitivity or severe reaction to either study drug. * Peripheral neuropathy from any cause \>Grade 1. * Pregnant or lactating patients or patients expecting to conceive children within the projected duration of the trial, starting with the Screening Visit through at least 3 months after the last dose of relacorilant, or per the duration indicated in the product label for nab-paclitaxel, whichever is latest. * Human immunodeficiency virus or current chronic/active infection with hepatitis C virus or hepatitis B virus, including: * Patients with chronic or active hepatitis B as diagnosed by serologic tests are excluded from the study. In equivocal cases, hepatitis B or C polymerase chain reaction may be performed and must be negative for enrollment. * Patient has a clinically significant uncontrolled condition(s) or which in the opinion of the Investigator may confound the results of the trial or interfere with the patient's participation, including but not limited to: * Unstable angina pectoris, angioplasty, cardiac stenting, or myocardial infarction 6 months before study entry. * Uncontrolled hypertension (sustained systolic blood pressure \>150 mmHg or diastolic pressure \>100 mmHg despite optimal management). Patients will be considered eligible if hypertension is treated and controlled during Screening. * Active infection that requires parenteral antibiotics. * Bowel obstruction or gastric outlet obstruction. * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. * Untreated parenchymal central nervous system metastases. * Any other concurrent cancer or a history of another invasive malignancy within the last 3 years that has a likelihood of recurrence of \>30% within the next 5 years. Adequately treated non-melanoma skin cancers or non-muscle invasive urothelial cancer or other tumors curatively treated with no evidence of disease are permissible. * Are taking a concomitant medication that is a strong CYP3A inhibitor or inducer, or that is a substrate of CYP3A with a narrow therapeutic window. * Concurrent treatment with mifepristone or other glucocorticoid receptor (GR) antagonists. * Concurrent treatment on other investigational treatment studies for the treatment of ovarian, fallopian tube, or primary peritoneal cancer. * Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) | Baseline and up to 15 months | To assess time from randomization until the date of first documented progressive disease (PD) by RECIST v1.1 (as determined by the Investigator at the local site), or death due to any cause, whichever occurs first. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | Up to 31 months | To assess the time from randomization to death by any cause. |
| Objective Response Rate (ORR) | Baseline and up to 15 months | To assess the proportion of patients with measurable disease at Baseline who attain complete response (CR) or partial response (PR) by RECIST v1.1 (confirmation not required). |
| Duration of Response (DOR) | From first documented response up to 12 months | To assess the time from when response (CR or PR) was first documented to the first objectively documented PD or death (whichever occurs first) |
| Cancer Antigen 125 (CA-125) Response According to Gynecological Cancer Intergroup Criteria (GCIG) | Baseline and up to 15 months | To assess the overall CA-125 response per GCIG criteria. Response was defined as ≥50% reduction in CA-125 from a pre-treatment sample. Patients whose CA-125 levels fall within the reference range are classified as complete responders. |
| Best Overall Response (BOR) | Baseline and up to 15 months | To assess the best response (CR, PR, stable disease \[SD\], or PD) recorded from the date of randomization until PD/recurrence (or death) |
| BOR in Patients Who Cross Over to Continuous Treatment at Time of Initial PD | Crossover Baseline (Day 50) up to Day 272 | To assess the best overall response (CR, PR, SD, or PD) recorded in the crossover period |
| PFS in Patients Who Cross Over to Continuous Treatment at Time of Initial PD | Crossover Baseline (Day 50) up to Day 272 | To assess the time from crossover Baseline (initial PD) until the earliest date of subsequent PD by RECIST v1.1, as determined by the Investigator at the local site, or death from any cause, whichever comes first. |
| ORR in Patients Who Cross Over to Continuous Treatment at Time of Initial PD | Crossover Baseline (Day 50) up to Day 272 | To assess the proportion of patients with measurable disease at the crossover Baseline who attain confirmed CR or PR by RECIST v1.1 |
| DOR in Patients Who Cross Over to Continuous Treatment at Time of Initial PD | From the time of objective response in the crossover period to the time of subsequent PD | To assess the time from when the first objective response (CR or PR) in the crossover period to the first objectively documented subsequent PD, or death (whichever occurs first) |
| Overall Response According to Combined RECIST v1.1 + GCIG Criteria | Baseline and up to 15 months | To assess the proportion of patients with measurable disease at Baseline who attain confirmed CR or PR by RECIST v1.1 and GCIG criteria. GCIG response was defined as ≥50% reduction in CA-125 from a pre-treatment sample. |
| PFS Rate at 6 and 12 Months | 6 and 12 months | To assess the proportion of patients who have not progressed according to RECIST v1.1 criteria at 6 and 12 months. Values are Kaplan-Meier estimates of the patients progression-free at the time points specified. |
Countries
Belgium, Canada, Italy, Spain, United States
Participant flow
Recruitment details
The intent-to-treat (ITT) population included all randomized patients.
Participants by arm
| Arm | Count |
|---|---|
| Arm A: Continuous Relacorilant Dosing Patients will receive relacorilant 100 mg (titrated up to 150 mg after Cycle 1 or 2) once daily in combination with nab-paclitaxel 80 mg/m\^2, on Days 1, 8, and 15 of each 28-day cycle. | 58 |
| Arm B: Intermittent Relacorilant Dosing Patients will receive relacorilant 150 mg on the day before (excluding Cycle 1, Day -1), the day of, and the day after nab-paclitaxel, in combination with nab-paclitaxel 80 mg/m\^2, on Days 1, 8, and 15 of each 28-day cycle. | 60 |
| Arm C: Nab-paclitaxel Comparator Patients will receive nab-paclitaxel 100 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle. Patients initially in Arm C who choose to cross over after disease progression will receive relacorilant 100 mg (titrated up to 150 mg) in combination with nab-paclitaxel 80 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle after cross over. | 60 |
| Total | 178 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Death | 53 | 49 | 56 |
| Overall Study | Did not enter long-term follow-up | 3 | 3 | 2 |
| Overall Study | Lost to Follow-up | 1 | 1 | 0 |
| Overall Study | Withdrawal by Subject | 1 | 7 | 2 |
Baseline characteristics
| Characteristic | Arm A: Continuous Relacorilant Dosing | Arm B: Intermittent Relacorilant Dosing | Arm C: Nab-paclitaxel Comparator | Total |
|---|---|---|---|---|
| Age, Continuous | 60.6 years STANDARD_DEVIATION 8.8 | 60.3 years STANDARD_DEVIATION 9.7 | 61.8 years STANDARD_DEVIATION 8.8 | 60.9 years STANDARD_DEVIATION 9.1 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 3 Participants | 3 Participants | 6 Participants | 12 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 53 Participants | 54 Participants | 49 Participants | 156 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 2 Participants | 3 Participants | 5 Participants | 10 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 3 Participants | 3 Participants | 6 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 1 Participants | 1 Participants | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 4 Participants | 5 Participants | 10 Participants |
| Race (NIH/OMB) White | 57 Participants | 52 Participants | 50 Participants | 159 Participants |
| Sex: Female, Male Female | 58 Participants | 60 Participants | 60 Participants | 178 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 53 / 58 | 49 / 60 | 56 / 60 |
| other Total, other adverse events | 57 / 57 | 59 / 60 | 60 / 60 |
| serious Total, serious adverse events | 30 / 57 | 15 / 60 | 19 / 60 |
Outcome results
Primary
Progression-free Survival (PFS)
To assess time from randomization until the date of first documented progressive disease (PD) by RECIST v1.1 (as determined by the Investigator at the local site), or death due to any cause, whichever occurs first.
Time frame: Baseline and up to 15 months
Population: The ITT population included all randomized patients.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Continuous Relacorilant Dosing | Progression-free Survival (PFS) | 5.29 months |
| Arm B: Intermittent Relacorilant Dosing | Progression-free Survival (PFS) | 5.55 months |
| Arm C: Nab-paclitaxel Comparator | Progression-free Survival (PFS) | 3.76 months |
p-value: 0.329395% CI: [0.56, 1.22]Cox proportional hazards model
p-value: 0.038495% CI: [0.44, 0.98]Cox proportional hazards model
Secondary
Best Overall Response (BOR)
To assess the best response (CR, PR, stable disease \[SD\], or PD) recorded from the date of randomization until PD/recurrence (or death)
Time frame: Baseline and up to 15 months
Population: Patients in the ITT population with measurable disease at Baseline
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arm A: Continuous Relacorilant Dosing | Best Overall Response (BOR) | Progressive disease | 9 Participants |
| Arm A: Continuous Relacorilant Dosing | Best Overall Response (BOR) | Stable disease | 23 Participants |
| Arm A: Continuous Relacorilant Dosing | Best Overall Response (BOR) | Complete response | 4 Participants |
| Arm A: Continuous Relacorilant Dosing | Best Overall Response (BOR) | Partial response | 15 Participants |
| Arm A: Continuous Relacorilant Dosing | Best Overall Response (BOR) | Not evaluable | 3 Participants |
| Arm B: Intermittent Relacorilant Dosing | Best Overall Response (BOR) | Stable disease | 20 Participants |
| Arm B: Intermittent Relacorilant Dosing | Best Overall Response (BOR) | Complete response | 1 Participants |
| Arm B: Intermittent Relacorilant Dosing | Best Overall Response (BOR) | Partial response | 19 Participants |
| Arm B: Intermittent Relacorilant Dosing | Best Overall Response (BOR) | Progressive disease | 14 Participants |
| Arm B: Intermittent Relacorilant Dosing | Best Overall Response (BOR) | Not evaluable | 2 Participants |
| Arm C: Nab-paclitaxel Comparator | Best Overall Response (BOR) | Not evaluable | 1 Participants |
| Arm C: Nab-paclitaxel Comparator | Best Overall Response (BOR) | Progressive disease | 12 Participants |
| Arm C: Nab-paclitaxel Comparator | Best Overall Response (BOR) | Complete response | 2 Participants |
| Arm C: Nab-paclitaxel Comparator | Best Overall Response (BOR) | Stable disease | 21 Participants |
| Arm C: Nab-paclitaxel Comparator | Best Overall Response (BOR) | Partial response | 17 Participants |
Secondary
BOR in Patients Who Cross Over to Continuous Treatment at Time of Initial PD
To assess the best overall response (CR, PR, SD, or PD) recorded in the crossover period
Time frame: Crossover Baseline (Day 50) up to Day 272
Population: Patients in the ITT population initially in Arm C: Nab-paclitaxel Comparator, who choose to cross over after disease progression and have measurable disease at the crossover Baseline.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arm A: Continuous Relacorilant Dosing | BOR in Patients Who Cross Over to Continuous Treatment at Time of Initial PD | Complete response | 0 Participants |
| Arm A: Continuous Relacorilant Dosing | BOR in Patients Who Cross Over to Continuous Treatment at Time of Initial PD | Partial response | 0 Participants |
| Arm A: Continuous Relacorilant Dosing | BOR in Patients Who Cross Over to Continuous Treatment at Time of Initial PD | Stable disease | 3 Participants |
| Arm A: Continuous Relacorilant Dosing | BOR in Patients Who Cross Over to Continuous Treatment at Time of Initial PD | Progressive disease | 18 Participants |
| Arm A: Continuous Relacorilant Dosing | BOR in Patients Who Cross Over to Continuous Treatment at Time of Initial PD | Not evaluable | 0 Participants |
Secondary
Cancer Antigen 125 (CA-125) Response According to Gynecological Cancer Intergroup Criteria (GCIG)
To assess the overall CA-125 response per GCIG criteria. Response was defined as ≥50% reduction in CA-125 from a pre-treatment sample. Patients whose CA-125 levels fall within the reference range are classified as complete responders.
Time frame: Baseline and up to 15 months
Population: Patients in the ITT population with an initial CA-125 level ≥ twice the upper limit of normal (ULN) of the reference range.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm A: Continuous Relacorilant Dosing | Cancer Antigen 125 (CA-125) Response According to Gynecological Cancer Intergroup Criteria (GCIG) | 32 Participants |
| Arm B: Intermittent Relacorilant Dosing | Cancer Antigen 125 (CA-125) Response According to Gynecological Cancer Intergroup Criteria (GCIG) | 34 Participants |
| Arm C: Nab-paclitaxel Comparator | Cancer Antigen 125 (CA-125) Response According to Gynecological Cancer Intergroup Criteria (GCIG) | 28 Participants |
Secondary
DOR in Patients Who Cross Over to Continuous Treatment at Time of Initial PD
To assess the time from when the first objective response (CR or PR) in the crossover period to the first objectively documented subsequent PD, or death (whichever occurs first)
Time frame: From the time of objective response in the crossover period to the time of subsequent PD
Population: No crossover patients attained CR or PR, so duration of response could not be analyzed.
Secondary
Duration of Response (DOR)
To assess the time from when response (CR or PR) was first documented to the first objectively documented PD or death (whichever occurs first)
Time frame: From first documented response up to 12 months
Population: Patients in the ITT population with measurable disease at Baseline and who attain CR or PR by RECIST v1.1.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Continuous Relacorilant Dosing | Duration of Response (DOR) | 3.79 months |
| Arm B: Intermittent Relacorilant Dosing | Duration of Response (DOR) | 5.55 months |
| Arm C: Nab-paclitaxel Comparator | Duration of Response (DOR) | 3.65 months |
Secondary
Objective Response Rate (ORR)
To assess the proportion of patients with measurable disease at Baseline who attain complete response (CR) or partial response (PR) by RECIST v1.1 (confirmation not required).
Time frame: Baseline and up to 15 months
Population: Patients in the ITT population with measurable disease at Baseline
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm A: Continuous Relacorilant Dosing | Objective Response Rate (ORR) | 19 Participants |
| Arm B: Intermittent Relacorilant Dosing | Objective Response Rate (ORR) | 20 Participants |
| Arm C: Nab-paclitaxel Comparator | Objective Response Rate (ORR) | 19 Participants |
Secondary
ORR in Patients Who Cross Over to Continuous Treatment at Time of Initial PD
To assess the proportion of patients with measurable disease at the crossover Baseline who attain confirmed CR or PR by RECIST v1.1
Time frame: Crossover Baseline (Day 50) up to Day 272
Population: Patients in the ITT population initially in Arm C: Nab-paclitaxel Comparator, who choose to cross over after disease progression and have measurable disease at the crossover Baseline.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm A: Continuous Relacorilant Dosing | ORR in Patients Who Cross Over to Continuous Treatment at Time of Initial PD | 0 Participants |
Secondary
Overall Response According to Combined RECIST v1.1 + GCIG Criteria
To assess the proportion of patients with measurable disease at Baseline who attain confirmed CR or PR by RECIST v1.1 and GCIG criteria. GCIG response was defined as ≥50% reduction in CA-125 from a pre-treatment sample.
Time frame: Baseline and up to 15 months
Population: Patients in the ITT population with an initial CA-125 level ≥ twice the ULN of the reference range within 2 weeks before starting treatment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm A: Continuous Relacorilant Dosing | Overall Response According to Combined RECIST v1.1 + GCIG Criteria | 34 Participants |
| Arm B: Intermittent Relacorilant Dosing | Overall Response According to Combined RECIST v1.1 + GCIG Criteria | 36 Participants |
| Arm C: Nab-paclitaxel Comparator | Overall Response According to Combined RECIST v1.1 + GCIG Criteria | 33 Participants |
Secondary
Overall Survival (OS)
To assess the time from randomization to death by any cause.
Time frame: Up to 31 months
Population: The ITT population included all randomized patients.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Continuous Relacorilant Dosing | Overall Survival (OS) | 11.30 months |
| Arm B: Intermittent Relacorilant Dosing | Overall Survival (OS) | 13.90 months |
| Arm C: Nab-paclitaxel Comparator | Overall Survival (OS) | 12.19 months |
Secondary
PFS in Patients Who Cross Over to Continuous Treatment at Time of Initial PD
To assess the time from crossover Baseline (initial PD) until the earliest date of subsequent PD by RECIST v1.1, as determined by the Investigator at the local site, or death from any cause, whichever comes first.
Time frame: Crossover Baseline (Day 50) up to Day 272
Population: Patients in the ITT population initially in Arm C: Nab-paclitaxel Comparator, who choose to cross over after disease progression.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Continuous Relacorilant Dosing | PFS in Patients Who Cross Over to Continuous Treatment at Time of Initial PD | 2.10 months |
Secondary
PFS Rate at 6 and 12 Months
To assess the proportion of patients who have not progressed according to RECIST v1.1 criteria at 6 and 12 months. Values are Kaplan-Meier estimates of the patients progression-free at the time points specified.
Time frame: 6 and 12 months
Population: The ITT population included all randomized patients.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm A: Continuous Relacorilant Dosing | PFS Rate at 6 and 12 Months | 6 months | 0.26 proportion of patients |
| Arm A: Continuous Relacorilant Dosing | PFS Rate at 6 and 12 Months | 12 months | 0.08 proportion of patients |
| Arm B: Intermittent Relacorilant Dosing | PFS Rate at 6 and 12 Months | 6 months | 0.40 proportion of patients |
| Arm B: Intermittent Relacorilant Dosing | PFS Rate at 6 and 12 Months | 12 months | 0.11 proportion of patients |
| Arm C: Nab-paclitaxel Comparator | PFS Rate at 6 and 12 Months | 6 months | 0.25 proportion of patients |
| Arm C: Nab-paclitaxel Comparator | PFS Rate at 6 and 12 Months | 12 months | 0.04 proportion of patients |